Relistor Finally Cleared For Bigger Opioid-Induced Constipation Label

Extended bid for an sNDA of Progenics/Salix’ subcutaneous Relistor for chronic non-cancer pain ends in success, but Nektar/AstraZeneca’s recently-approved oral Movantik is expected to dominate the market. Regulatory path for Phase III oral Relistor is still unclear.